Lipum receives Vinnova funding for biomarker-guided development of SOL-116

The project brings together complementary expertise from the two companies. Lipum contributes its knowledge of Bile Salt-Stimulated Lipase (BSSL), therapeutic development and clinical strategy. Clairvoyant Diagnostics adds expertise in biomarker discovery, translational immunology, autoantibody profiling, protein-array technologies and diagnostic development.

The collaboration will identify the most promising biomarkers for SOL-116 and explore how they could be used in future studies. This may help improve the understanding of treatment response and support patient stratification. The initial focus will be rheumatoid arthritis, while the potential of BSSL inhibition in other chronic inflammatory diseases may be explored in the longer term.

“This funding enables us to deepen our collaboration with Clairvoyant Diagnostics and create a joint framework for future biomarker and translational studies. A stronger understanding of biomarkers and the mechanism of action of SOL-116 may support future clinical development and the continued positioning of SOL-116 in rheumatoid arthritis and other chronic inflammatory diseases,” says Ola Sandborgh, CEO at Lipum.

During the six-month project, the partners will establish a formal framework for collaboration and governance, evaluate scientific and technical opportunities and prioritize future biomarker and study concepts. We will also agree on principles for intellectual property and data sharing and develop a roadmap and funding strategy for continued Swedish-German and European research and innovation initiatives.

The activities funded within the project are focused on collaboration building, feasibility assessment and strategic planning. The total project budget is SEK 591 000 of which 499 000 is financed by Vinnova